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Background. NK cells are able to kill tumor and virus-infected cells without the need of prior antigen stimulation. The killing
of these target cells is regulated by inhibitory, lysis and co-stimulatory receptors that are expressed on the surface of NK cells.
Principal Findings. CD100 (Semaphorin 4D), a 150kD transmembrane protein, is expressed on the surface of activated NK
cells as a homodimer, mediates the killing of target cells by binding to CD72. CD100 is not involved directly in the killing
process but is rather increases NK cytotoxicity by enhancing the adhesion between NK cells and their targets. This increased
adhesion leads to a more efficient killing and enhanced IFNc secretion. Significance. Since CD72 is expressed on antigen
presenting cells (APC) and the CD100-CD72 interaction lead to the shading of CD100, we suggest that NK interacting with APC
cells could be the early source of soluble CD100 which is crucial for the formation of antigen specific immune response. CD100-
CD72 interaction can be the mechanism by which NK cell communicate with B cells.
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Expressing CD72. PLoS ONE 2(9): e818. doi:10.1371/journal.pone.0000818
INTRODUCTION
NK cells are part of the innate immunity system and are able to
kill tumor and virus-infected cells that have lost, in most cases,
class I MHC protein expression [1].The recognition of MHC class
I proteins by NK inhibitory receptors leads to inhibition of NK
killing and in the absence of MHC class I proteins, these inhibitory
constraints are removed and NK cytotoxicity is restored[2–9]. In
recent years it was realized however that NK cytotoxicity is much
more complicated [10] and that the killing of NK cells is also
controlled by activating receptors, among these are Natural
Cytotoxicity Receptors (NCRs), NKG2D, CD16 (low affinity
FccRIII), 2B4 and NKp80 [11]. NK cells are also capable of
producing cytokines, including TNFa, GM-CSF, and a large
quantity of IFNc. IFNc affect many cellular responses, including
the control of viral replication, up-regulation of MHC class I
and class II protein expression and activation of macrophages. It
can also direct the adaptive immune responses towards the Th1
type [12].
The semaphorins which are characterized by ‘‘Sema’’ domain
(,500 A.A.) in their extracellular region were initially recognized
for their role as chemorepellents during neural development [13].
The semaphorin CD100 is the first semaphorin to be found on
the surface of immune cells[14–16] and is the best semaphorin
characterized so far [15,17–20]. Membrane bound CD100 is
a 150-kDa trans-membrane protein, express as a homodimer
[14–16] with high levels of expression both in lymphoid organs
such as thymus, spleen and lymph node, and on non- lymphoid
organs such as brain, kidney and heart [14,15,21].On hemato-
poietic cells it can be found on resting T cells, B cell,
macrophages, dendritic cells (DC) and its expression is up-
regulated significantly after cellular activation [15,16,22,23].
CD100 can be cleaved from the membrane to form a functional
soluble homodimer in the size of 240-kDa [24–26]. Two distinct
receptors were identified for CD100: plexin-B1, which is the high
affinity receptor for CD100, is found on many tissues with high
levels of expression in the fetal brain and kidney [27].The low
affinity receptor for CD100 is CD72, the major receptor for
CD100 in immune cells [22]. CD72 is expressed during all stages
of B cell maturation, except for plasma cells [22], and is also
expressed on other antigen presenting cells such as dendritic cells
and macrophages [28,29].
CD100 has many biological activities in the immune system. It
enhances B cells response to stimulation with CD40 and LPS both
in vitro and in vivo [15,16,22,23,30]. B cells derived from
CD100-/- knockout mice demonstrate a reduction in B cell
activity and antibodies specific to T cell dependent (TD) antigens
[31]. In contrast transgenic mice expressing functional soluble
CD100 demonstrate the reverse pattern [32].
CD100 has also been found to have an important function in
DC. CD100-deficient mice were resistant to autoimmune diseases
models such as experimental autoimmune encephalomyelitis
(EAE) [28] and immune complex glomerulonephritis (ICG) [33].
This effect was due to the lack of proper mature DC in the CD100
knockout mice. In human monocytes, soluble CD100 inhibits
migration and induce the production of pro-inflammatory
cytokines [28] and inhibit their migration [26,34]. Here, by
screening for novel antibodies that affect NK killing we identified
a new mAb that recognizes CD100. Using this mAb we
demonstrate a novel role for CD100 in the augmentation of NK
killing and cytokine secretion.
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Identification of 172.4 mAb which recognize ligand
that is up-regulated after activation of NK cells
Several NK receptors such as NKp44 on NK [35] and NKG2D
on T cells [36] are upregulated after activation. Based on that fact,
our assumption was that the level of other yet unknown NK
activating receptors is also up-regulated after NK cell activation.
In order to identify such receptors we immunized mice with the
NK cell line-YTS. 2000 hybriomas were obtained and the
supernatants of these hybridomas were tested for the binding to
IL-2 activated and non-activated peripheral blood lymphocytes
(PBL) by flow cytometry. Increased binding to IL-2 activated PBL
compared to fresh PBL was observed with the supernatant of
hybridoma 172 (data not shown). Hybridoma 172 was re-cloned
and a mAb was purified from the hybridoma sub line named
172.4. Supernatants from 172.4 were tested in binding to different
sub-population of activated and non-activated PBL. As shown in
Figure 1, 172.4 mAb recognizes a sub-population of resting NK, B
and T cells (figure 1 A, C, E). A dramatic increase in the binding of
172.4 to all tested populations was observed after 72 hr of
activation with IL-2 (figure 1 B, D and F). Almost all activated NK
cells express high levels of the ligand for 172.4 (93% in figure 1B).
To further characterize the 172.4 expression on NK cells, we
activated the NK cells with different stimuli. The two main NK
populations in the blood are CD16
2, CD56
bright and the CD16
+,
CD56
dim. They differ both in function and in expression of
different molecules on their surface [37,38]. Fresh PBMC were
incubated with different stimulates (50 ng/ml) for 72 hr and the
expression of 172.4-ligand on NK cells was analyze by flow
cytometry. As can be seen in figure 1G enhancement of 172.4-
ligand expression was observed only after incubation with IL-12
and more pronouncedly after incubation with IL-15. Both
cytokines are well known activators of NK cells [39,40]. In
contrast, incubation with IL-8, IL-6 and TNFa had no effect. IL-
12 stimulation of NK cells resulted in modest elevation of the
172.4-ligand on CD16
+ NK cells (median fluorescence intensity
(MFI) 90.2 verses 60.4 for the negative control) but not on CD16
2
cells (MFI of 59.9 verses 53.3 for the negative control). IL-15
treatment resulted in marked 172.4-ligand expression on both
populations (MFI of 235 and 269 in CD16
2 and CD16
+,
respectively).
Thus, the protein recognize by 172.4 mAb is elevated in
a response to a variety of activation stimuli which include IL-12,
IL-15 and IL-2 and therefore can serve as a marker of NK
activation.
The ligand recognized by 172.4 mAb is not directly
involved in the killing of target cells by NK cells
To test whether the protein recognized by 172.4 mAb is involved
in the regulation of NK cytotoxicity we performed lysis assays. IL-
2-activated NK cells were pre-incubated with various mAbs,
indicated in figure 2A, and then subjected to lysis assay with
35S-
labeled 721.221 or RPMI 8866 as target cells. No differences in
the lysis of 721.221 (figure 2A) or RPMI 8866 (data not shown)
were observed regardless of whether the control 12E7 mAb or
172.4 mAb were included in the assay. We concluded that the
protein recognized by mAb 172.4 is not directly involved in killing
of 721.221 or RPMI 8866 cells. However, it is still possible that the
Figure 1. Expression of the ligand of 172.4 on lymphocyte sub-populations and NK line. Biotinylated 172.4 mAb was used in combination with
other fluorescently labeled mAbs in a four color staining. 172.4 staining was detected using Cy-5 streptavidin. Cells were analyzed by flow cytometry.
T cells were identified as CD3 positive, NK cells as CD56 positive, CD3 negative, and B cells as CD19 positive. Staining was performed on freshly
isolated PBL (A, C and E) and on PBL that were cultured for 72 hr in the presence of IL-2 (100 u/ml) and human serum (B, D and F). Each dot blot
shows a gated specific sub-population. An isotype matched antibody was used to determent the background staining for each antibody and is
represented in the figure as the horizontal line. (H) Freshly isolated PBMC were incubated for 72 hr with 50 ng/ml of the indicated cytokines.
Biotinylated 172.4 mAb was detected using Cy-5 streptavidin and used in combination with other fluorescently labeled mAbs in a four color staining.
The PBL were analyzed for the expression of CD100 on NK cells and each dot plot represents a gated NK cells (CD3-, CD56+). Figure shows one
representative experiment out of four performed.
doi:10.1371/journal.pone.0000818.g001
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cells by NK cells. We, therefore, tested whether this protein is
involved in the regulation of NK cell-mediated cytotoxicity by
performing re-directed lysis experiments (figure 2B and 2C).
35S-
labeled P815 cells were incubated with different mAbs, as
indicated in figure 2B, and then incubated with NK cells. As
above, no differences were observed when either the control mAb
HC10 or mAb 172.4 were included in the assay. Thus the protein
recognized by172.4 is not directly involved in NK cytotoxicity.
Next, we tested whether the protein recognized by mAb 172.4
may act as co-stimulatory molecule on NK cells. P815 cells were
pre-incubated with increasing concentrations of the anti-CD16
mAb B73.1.1 combined either with mAb 172.4 or control mAb
12E7, and then incubated with the NK cells. Efficient lysis of P815
cells was observed even when cells were incubated with 0.02 mg/
ml of B73.1.1 mAb (figure 2C). As above, no differences in lysis of
P815 cell were observed when either mAb 12E7 or 172.4 mAb
were included in the assay together with B73.1.1. Thus, the
protein recognizes by mAb 172.4 is unlikely to be directly involved
in the regulation of NK cell cytotoxicity.
The protein recognized by mAb 172.4 is CD100
Toidentifythe proteinrecognized 172.4,we immunoprecipitated the
protein with mAb 172.4 from lysate of
125I-labeled YTS cells and
analyzed it by two-dimensional (non-reducing/reducing) SDS-
PAGE gel. As shown in figure 3A, mAb 172.4 immunoprecipitated
ama jo rp ro t e ino f,150kDa under reducing conditions.Thisprotein
runs as a broad band of about 150–300kDa under non-reducing
conditions (data not shown), thus implying that the 150kDa protein
recognized by mAb 172.4 could form homodimers (figure 3A). The
minor ,120kDa protein band, under reducing condition, that was
also precipitated by mAb 172.4 might be a proteolyticly cleaved
fragment (while the other minor 53kDa protein band is non-specific).
A data bank search suggested that the protein recognize by 172.4
might be CD100. CD100 is a 150kDa protein expressed as
300kDa homodimer protein on the surface of T cells and B cells
[14,16,25,41]. A soluble form, a homodimer composed of two sub-
units of 120kDa each has also been described [25,42].
To test whether the 172.4 mAb recognizes CD100 we first
performed flow cytometry analysis of various cell types, using both
172.4 and the commercial anti-CD100 mAb A8 and observed
identical staining patterns (data not shown). To prove that 172.4
recognize CD100 we used a fusion protein, composed of the
extracellular region of human CD100 fused to Fc region of human
IgG1 (CD100-Ig). We produced the CD100-Ig protein in COS-7
cells as previously described [43–45] and performed ELISA with
increasing concentrations of CD100-Ig and CD99-Ig (used as
control) fusion proteins. Figure 3 shows that both the commercial
anti-CD100 mAbs A8 (figure 3B) and 172.4 (figure 3D) recognized
CD100-Ig but not CD99-Ig, whereas 12E7 recognized only the
CD99-Ig (figure 3C).
To further verify that mAb 172.4 recognize human CD100 we
compare the staining of human NK line by 172.4 mAb to that of
the commercial mAb A8 (figure 3E). All activated NK cells were
stained positive for both antibodies and demonstrated an identical
pattern of staining for both antibodies.
We therefore concluded that mAb 172.4 recognize the protein
known as CD100.
CD100 on NK cells enhance the killing and IFNc
secretion after incubation with targets expressing
CD72
Human CD100 interacts with CD72, originally identified as a B
cell differentiation antigen [22]. To test whether the CD100-CD72
interaction will affect NK cytotoxicity we generated BW cells
stably expressing human CD72 (BW/CD72). BW cells were
chosen because their lysis by NK cells is relatively low and this
allows small differences in killing to be detected. IL-2 activated NK
cells killed more efficiently (up to 64% more at E: T ratio of 5:1)
BW cells expressing human CD72 then parental BW (Figure 4A).
Blocking of the interaction between CD100 and CD72 by pre-
incubating the target cells with CD100-Ig reduced the killing
compared with the control fusion protein CD8a-Ig (figure 4B),
indicating that the enhanced killing is due to CD100-CD72
interaction. In contrast, pre-incubation of BW cells with either
CD100-Ig or CD8a-Ig did not influence the killing of BW cells by
NK cells (figure 4C). Thus, CD100 is involved in NK cytotoxicity
probably as an adhesion molecule that enhancing the killing of
different target cells expressing CD72.
To test whether CD100-CD72 interactions would modify
cytokines secretion, freshly isolated NK cell were incubated with
Figure 2. Killing of target cells is not influence by mAb 172.4. (A)
35S-labeled 721.221 cells were pre-incubated with the indicated mAbs and tested
for lysis by NK cells at different effectors to targets (E:T) ratios as indicated in the figure. (B)
35S-labeled P815 cells were pre-incubated with the
indicated mAbs and tested for lysis by NK cells at the indicated E:T ratios. (C)
35S-labeled P815 cells were pre-incubated with the combination of the
indicated mAbs and tested for lysis by NK cells. E: T ratio of 10:1 is presented. Figure shows one representative experiment out of four performed.
doi:10.1371/journal.pone.0000818.g002
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ing cytokines for 72 hr (figure 4D). Fresh NK cells incubated with
BW or BW/CD72 cells did not secrete IFNc (figure 4D). However,
whenthe(NK)activatingcytokineswereaddedtotheassay,NKcells
that were incubated with BW/CD72 secreted significantly higher
amount of IFNc as compare to NK cells incubated with BW cells.
Figure 3. 172.4 recognize CD100, a 150kDa protein expressed as a homodimer. (A) Surface radioiodinated YTS cell lysate was immunoprecipitated
with mAb 172.4. The immunoprecipitate was analyzed first on non-reducing and then on reducing SDS-PAGE. The left lane is an aliquot of
immunoprecipitated proteins resolved under reducing conditions. Molecular weight markers are as shown. The two forms of CD100 (150 and
120 kDa respectively) are indicated with arrows. (B, D) ELISA plates were coated with CD100-Ig and assayed for binding to the indicated antibodies as
described in ‘‘Materials and Methods’’. (C) ELISA plates were coated with CD99-Ig and assayed for binding to the indicated antibodies as described in
‘‘Materials and Methods’’. The background binding to BSA was subtracted. Figure shows one representative experiment out of four performed. (E) IL-
2 activated NK line was stained with either 172.4 or the commercial anti human CD100 antibody A8. FITC conjugated Goat F(ab’) anti mouse IgG
antibody was used as secondary Ab. Gray histogram is staining with secondary antibody only. Figure show one representative experiment out of 5
performed.
doi:10.1371/journal.pone.0000818.g003
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the secretion of TNFa or GM-CSF were observed when NK cells
were incubated either with BW or BW/CD72 (data not shown).
CD100 on NK cells is an adhesion protein
To verify that CD100 function as an adhesion molecule on NK
cells we preformed an adhesion assay in which BW or BW/CD72
cells were incubated on 96 flat bottom plate for two hours at 37uC.
35S-Met labeled-IL-2-activated NK cells were then added to the
plate, washed and radioactivity was measured. As shown in
figure 5A, NK cells adhere more strongly to BW cells expressing
CD72 compared with BW cells. Blocking CD100-CD72 in-
teraction by pre-incubating BW/CD72 with CD100-Ig reduce the
adhesion between the NK cells to the target cells (figure 5B). To
further confirm that CD100 is an adhesion molecule on NK cells,
we performed signaling experiments. IL-2-activated NK were
incubated with BW/CD72 or BW cells for short period of time
and then lysed. CD100 was immunoprecipitated with 172.4 mAb.
The proteins were eluted under reduce condition and separated on
an SDS-PAGE. Western blot analysis with antibody directed
against phosphorylated serine residues revealed that cross linking
of CD100 by CD72 led to an increase in phosphorylation on
serine residues in three unknown proteins that are associated with
CD100 (indicated by arrows, figure 5C). In contrast, when NK
cells were incubated with BW cells the level of serine phosphor-
ylation did not change or even slightly decreased. To confirm that
equal levels of proteins were precipitated in the various treatments,
we re-blot the membranes with anti CD100 mAb A8. As shown in
figure 5C the level of CD100 is equal in all the lanes. Thus, the
changes observed in the levels of serine phosphorylation are
genuine. These results were confirmed by the quantification of the
level of phosphorylation using densitometrical analysis (figure 5D).
Thus CD100 on activated NK cells strengthens their binding to
target cells expressing CD72. The interaction with CD72 leads to
increase in serine phosphorylation found in unknown proteins
associated with CD100.
DISCUSSION
By immunization of mice with the NK cell line YTS we were able
to isolate one mAb named 172.4 that recognized the CD100
protein. The expression of CD100 is up-regulated on the surface of
NK cells after their activation with IL-2, IL-12 and IL-15 (figure 1),
implicating CD100 as activation marker for NK cells. CD100 can
also be used to distinguish between the states of activation of the
CD16
+ and CD16
2 NK cell populations. Activation of NK cells
with IL-12 elevated the level of CD100 on CD16
+ but not on
CD16
2 NK cells compare with IL-15 which elevated the level of
CD100 on both populations (figure 1).
Figure 4. NK cytotoxicity and IFNc secretion is enhanced after binding to CD72. (A)
35S-labeled BW or BW/CD72 cells were tested for lysis by
activated NK cells at different effectors to targets ratio as indicated in the figure. *p,0.005. (B)
35S-labeled BW/CD72 cells were pre-incubated with the
indicated fusion proteins and tested for lysis by activated NK cells at the indicated E:T ratios.*p,0.05. (C)
35S-labeled BW cells were pre-incubated
with the indicated fusion proteins and tested for lysis by activated NK cells at the indicated E:T ratios. The differences observed between the various
treatments were not statistically significant. (D) NK cells were incubated with BW or BW/CD72 in the presence or absence of the various cytokines
indicated in the figure and IFNc secretion was measured by ELISA. Figure shows one representative experiment out of four performed. * p=0.03,
**p=0.01
doi:10.1371/journal.pone.0000818.g004
CD100 Enhance Killing
PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e818We demonstrated hat CD100 is not a lysis receptor but could
instead enhance the killing and cytokine secretion by interacting
with its ligand CD72. The interactions between CD100 and CD72
might be important in killing of transformed cells such as leukemia
of B cell origin, which express CD72 on their surface [29,46–48].
It has long been established that NK cells can interact directly
with dendritic cells [49] and macrophages [50]. It is known that
NK cells not only influence DC function via cytokine secretion but
also via direct killing [51]. Since CD72 is expressed on antigen
presenting cells like B cells, macrophages and dendritic cells, the
interaction with NK might also influence the function of these cells
via the CD100-CD72 interactions. Of a special note is the possible
cross-talk between NK cells and B cells. The fact that that NK
express both CD100 and CD40L and the B cells express their
counterpart CD72 and CD40 imply that these cells may interact
directly. It was demonstrated that soluble CD100 (sCD100) is
crucial for the development of Ag-specific immune responses to T
cells-dependent (TD) Ag [28,32,33]. The immune responses can
be restore in these mice by applying sCD100 [28,32]. But what
could be the early source of sCD100? .Both T cell and B cell,
express CD100 but they can only release sCD100 after their
activation [15,16,22,23] and thus could not be the initial source for
sCD100. This raises the possibility that anther cell, probably
belonging to the innate system is responsible for early release of
sCD100.
We demonstrate here that NK can produce sCD100 form
(,120kDa, figure 3A) and also observed that IL-2-activated NK
cells secrete sCD100 (data not shown) and thus we suggest that
NK cells are the early source for CD100. We propose the
following model. NK cells are activated at the infection site meet
APC and secrete sCD100. They interact with APC by several
routs among which is the CD100-CD72 interactions. Such
interactions lead to IFNc and sCD100 secretion which in turns
activates other cells of the immune system.
Figure 5. The interaction between CD100 and CD72 leads to the phosphorylation of serine residues on proteins associate with CD100. (A)
35S-labeled activated NK cells were incubated for 20 minutes with adherent BW or BW/CD72 cells. The wells were washed, the remaining cells
were lysed and the level of radioactivity was measured in CPM units (counts per mint). The results presented after subtraction of NK cells only. (B)
35S-
labeled activated NK cells were incubated for 20 minutes with adherent BW/CD72 cells that were pre incubated with CD100-Ig or CD99-Ig for 2 hr
prior to the incubation with NK cells. The wells were washed, the remaining cells were lysed and the level of radioactivity was measured. *p=0.02. (C)
Activated NK cells were incubated with target cells (BW or BW/CD72), in 37uC, for the indicated time periods. Cells were lysed and proteins were
immunoprecipitated by mAb 172.4. The immunoprecipitated proteins were separated on a reducing SDS-PAGE. Phosphorylated proteins were
detected in western blot by using rabbit anti phospho-serine polyclonal Ab. CD100 levels were detected in western blot by using the A8 anti human
CD100. (D) Densitometrical analysis of the level of phosphorylation on serine residues of the three proteins indicated by arrows in Figure 5C. The
levels of phosphorylation are relative to their level at time zero which was set as one. Figure shows one representative experiment out of two
performed.
doi:10.1371/journal.pone.0000818.g005
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Cells and transfections
The cell lines used were the MHC class I-negative human EBV-
transformed B cell line 721.221, simian kidney cells COS-7 and
the a/b TCR-negative mouse tymoma BW. Cell lines were grown
in complete RPMI-1640 or DMEM (supplemented with 10%
FBS, 1 mM L-glutamin, 1 mM penicillin-streptomycin, 1 mM
non-essential amino acids and 1 mM sodium pyruvate (Gibco,
Minneapolis, MN)). NK cells were isolated from peripheral blood
mononuclear cells (PBMC) using the human NK cell isolation kit
and an autoMACS instrument (Miltenyi Biotec, Bergisch-Glad-
bach, Germany.). NK cells were grown as previously described
[43–45]. BW cell were transfected with pcDNA3.1/V5-His-
TOPO (Invitrogen, Carlsbad, CA) contaning the cDNA of human
CD72 (BW/CD72). BW/CD72 cells were grown in complete
medium RPMI-1640 supplemented with 5 mg/ml G418 (Gibco).
The Human CD72 gene was amplified from 721.221 cells using
the 59 primer (with Kozak and Kpn I site): GGTACCCGCCGC-
CACCATGCTGAGGCCATCACCTATG and the 39 primer
(with Xba I site): GCTCTAGAGCCTAATCTGGAAACCT-
GAAAGCTAT. The hCD72 was inserted into the plasmid with
the TOPO TA expression Kit (Invitrogen).
Monoclonal antibodies used in this work were mAb B73.1.1,
directed against CD16 (IgG1), A8 directed against CD100
(Serotec, Oxford, U.K), 3F3 directed against CD72 (Serotec),
12E7 directed against CD99 (IgG1), HC10 directed against the
free heavy chain of MHC class I and mAb 172.4 directed against
human CD100 (IgG1). For flow cytometry analysis the following
Abs were used: PE-conjugated mouse anti-human CD19 (BD
PharMingen, San Diego, CA), Cy-Chrome-conjugated mouse
anti-human CD3 (BD Pharmingen), FITC-conjugated mouse anti-
human CD56 (Serotec), FITC-conjugated mouse anti-human
CD16 (Dako, Glostrup, Denmark), 172.4 mAb biotinylated was
used as first Ab and then Cy-5 conjugated streptavidin (Jackson
Immunoresearch, West Grove, PA).
Cytotoxicity assays
The cytotoxic activity of NK cells against the various targets was
assayed in 5-hr
35S-release assays, as described previously [43–45].
In all presented cytotoxic assays, the spontaneous release was less
than 20% of maximal release. In some assays the NK cells were
pre-incubated with 0.5 mg/well of each antibody 1 hr on ice prior
to the experiment. In the Re-directed lysis experiment target cells
were pre-incubated with increasing concentration of anti-CD16
mAb B73.1.1 with or without 0.1 mg/well of the indicated mAbs.
In some assays the target cells were pre-incubated with 40 ng/ml
of each fusion protein 2 hours on ice prior to the experiment.
Radioiodination, immunoprecipitation, and two-
dimensional SDS-PAGE
YTS cells were radioiodinated with 1 mCi of Na
125I (ICN
Biomedicals, Inc., Irvine, CA) by the lactoperoxidase method.
After extensive washes with cold PBS, labeled cells were
solubilized on ice with 0.5% Nonidet P-40/10 mM iodoaceta-
mide/5 mM EDTA/1 mM PMSF/10 mM leupeptin and pepsta-
tin A in PBS, pH 8.3 (lysis buffer). Cell lysates (1610
6 cells/
sample) were precleared on ice with protein A coupled sepharose
beads (Zymed Laboratories Inc, S. San Francisco, CA) precoated
with rabbit anti-mouse IgG. Aliquots of precleared lysates were
then immunoprecipitated overnight at 4uC with protein A coupled
sepharose beads precoated with rabbit anti-mouse IgG and mAb
172.4 or control IgG1 mAb. Immunoprecipitated samples were
washed with lysis buffer, and labeled proteins were eluted in the
presence of SDS under non-reducing conditions. Non-reduced
samples were separated on SDS-PAGE. The gels were then cut
into strips, each representing an immunoprecipitate, reduced with
2% (V/V) 2-mercaptoethanol at 37uC for 1 hr, and placed on top
of the second dimension SDS-PAGE followed by autoradiogra-
phy. For detection of phosphorylated proteins, NK cells were first
activated by coincubating 20610
6 NK cells per sample and
20610
6 BW/CD72 cells or BW in 500 ml complete RPMI-1640
medium at 37uC. After activation cells were immediately washed
four times with ice cold PBS containing 1:100 phosphatase
inhibitor cocktail II (Sigma-Aldrich, Inc, St Louis, MO). Cells
were lysed with 500 ml of lysis buffer (150 mM NaCl/50 mM Tris
(pH 7.6)/0.5% Nonidet P-40/5 mM EDTA) supplemented with
1:100 aprotinin (Sigma-Aldrich)/1 mM PMSF and 1:100 of
phosphatase inhibitor cocktail II (Sigma-Aldrich). Aliquots were
precleared on ice with protein A coupled sepharose beads (Zymed
Laboratories, Inc.) precoated with irrelevant mouse IgG. Aliquots
of precleared lysates were then immunoprecipitated overnight at
4uC with protein A coupled sepharose beads precoated with mAb
172.4. . Immunoprecipitated samples were washed four times with
lysis buffer and proteins were eluted in the presence of SDS under
reducing conditions. Samples were separated on SDS-PAGE and
phosphorylated proteins were visualized by pAbs rabbit anti-
phosphoserine (Stressgen, Victoria, BC) and EnVision+ system
(Dako). The level of phosphorylation was quantified using the
ImageMaster VDS-CL (Amersham Pharmacia biotech, Piscat-
away, NJ) densitometer. Level of CD100 was detected by using the
commercial anti human CD100 antibody A8 (serotec).
ELISA
96 wells MaxiSorp plates (Nunc, Roskilde, Denmark) were pre-
coated overnight at 4uC with increasing concentrations of various
fusion proteins in 50 ml of PBS per well. Plates were washed three
times with washing buffer (PBS+0.5% Tween 20) and blocked with
200 ml of 1% BSA in PBS for 2 hr on ice. Plates were washed
three times with washing buffer and incubated overnight at 4uC
with 0.1 mg/well of indicated antibodies in 100 ml of blocking
buffer/Tween (PBS+1% BSA+0.05% Tween 20). Plates were
washed 4 times with washing buffer and incubated for 1 hr on ice
with 100 ml of goat anti-mouse IgG (H+L)-AP conjugated (Bio-
Rad, Hercules, CA), diluted 1/2000 in blocking buffer/Tween .
Plates were washed six times with washing buffer and incubated
for 30–50 min at room temperature with alkaline phosphatase
substrate kit (Bio-Rad). Optical density was measured in an ELISA
reader at 405 nm.
For the detection of IFNc secreted by NK cells, 100,000 NK
cells per well were incubated with 100,000 BW or BW/CD72 cells
in 200 ml of complete RPMI-1640 on flat bottom plate for
72 hours at 37uC with or without 20 ng/ml of the indicated
cytokines (Pepro tec.). The ELISA for the detection of human
IFNc was performed in accordance with the manufacture protocol
and reagents (PharMingen)
Adhesion assay
NK cells were label with
35S-Met as described previously [43–45].
100,000 BW or BW/CD72 cells per well were incubated in 50 ml
complete RPMI-1640 (Gibco) for 2 hr in 37uC on 96 flat bottom
plates (Nunc). 50,000 NK cells in 50 ml complete RPMI-1640
medium were added to the plate and incubated for anther
20 minutes at 37uC. The medium was aspirated from the plate
gently and then the plate was washed once with 200 ml PBS.
100 ml of RPMI-1640 was added to each well and cells were lysed
CD100 Enhance Killing
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as describe before [43–45]. In some assays the target cells were
pre-incubated with 40 ng/ml of CD100-Ig or CD99-Ig, 2 hours in
37uC prior to the experiment.
Activation of cells with cytokines
PBMC were incubated in 37uC for 72 hr with 50 ng/ml of
different cytokines in complete RPMI-1640 medium (Pepro tec.,
London, U.K).
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